Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"University of Louisville","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Research Findings Published in Pharmaceuticals Identify Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"DecentraNet","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maxwell Biosciences Announces In Vivo and In Vitro Data on CLAROMER Platform\u2019s Ability to Treat and Prevent SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Maxwell Biosciences

    Menu

    Maxwell Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Maxwell Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Maxwell Biosciences Announces In Vivo and In Vitro Data on CLAROMER Platform’s Ability to Treat and Prevent SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Confere...

              Details:

              The CLAROMER drug discovery platform generates a family of novel compounds to precisely target infectious pathogens. CLAROMERS can exhibit improved stability and potency relative to natural peptides and are highly scalable to manufacture.

              Lead Product(s): Antimicrobial Peptides

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Maxwell Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round

              Details:

              The funding will enable Maxwell to accelerate the development of its innovative platform having LL-37, recruit and retain top talent, pursue clinical trials, and scale up manufacturing capabilities.

              Lead Product(s): Ropocamptide

              Therapeutic Area: Infections and Infectious Diseases Product Name: LL-37

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: DecentraNet

              Deal Size: $10.8 million Upfront Cash: Undisclosed

              Deal Type: Financing March 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Maxwell Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Research Findings Published in Pharmaceuticals Identify Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2

              Details:

              Titled Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids, the research findings demonstrate that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: University of Louisville

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY